An observational study in Patient Reported Outcomes, Patient Satisfaction and Long Term Outcomes, sponsored by Versailles Hospital. Recruiting at 19 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.
Sponsored by Versailles Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Patient Satisfaction with a site in France — 16 open to participants now, 18 under way, none of them phase 3. Patient Satisfaction · France.
Among the 43 studies in Patient Satisfaction with a site in France, this one is the 14th largest by planned enrollment of the 25 observational ones that give a count, is one of 3 that started in 2024, is one of 25 observational ones, reaches primary completion later than 10 of the 17 other live ones, and was the 24th registered.
882 studies on the registry are indexed under Patient Satisfaction; 205 are open to participants now.
Browse Patient Satisfaction studies →16 of the 43 studies in Patient Satisfaction with a site in France are open now. Recruiting first, the newest first:
CHI MONT DE MARSAN ET PAYS DES SOURCES · Sites in France
Ages 18+
Suisselle · Sites in France
Ages 35+ · Healthy volunteers
University Hospital, Angers · Sites in France
Ages 18+
Centre Hospitalier de Martigues · Sites in France
Ages 18+
Centre Hospitalier Intercommunal Creteil · Sites in France
Ages 18+ · Women only
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 102 Patient Satisfaction studies recruiting now, 63 (62%) set no upper age limit and 31 (30%) stop at 75 or younger; 14 take children under 18; 26 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 145 is close to the median of 150 across 227 observational studies indexed under Patient Satisfaction.
Median enrollment 132 across the 18 interventional studies, 150 across the 25 observational. Of the 19 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 43 have an industry lead sponsor. The 10 most frequent:
Versailles Hospital is the lead sponsor of 74 studies on the registry; 16 are open to participants now.
Versailles Hospital has 1 study filed under Patient Satisfaction — fewer than ten, so there is no comparison to draw.
8 of the studies in Patient Satisfaction with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07668050University Hospital, Clermont-FerrandA Study of the Impact of a Virtual Reality Medical Device (HypnoVR® Headset) on Anxiety and Pain in Interventional Radiology. | 2026-12 |
| NCT07557589CHI MONT DE MARSAN ET PAYS DES SOURCESRadiofrequency Treatment for Pilonidal Disease : Clinical Investigation on Safety of Use, Efficacy and Patient Satisfaction at 6 Months | 2027-01 |
| NCT06100978Versailles HospitalPatient-reported Outcome and Patient-reported Experience After Status Epilepticus | 2027-03-25 |
| NCT07721350Hospices Civils de LyonProspective Evaluation of Subcutaneous Administration of Daratumumab by the FreedomEDGE® Infusion System | 2027-05 |
| NCT07146659Centre Hospitalier Intercommunal CreteilComparison of Operative Hysteroscopy Performed in the Operating Room Versus Outpatient Settings | 2027-05-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 43 studies in Patient Satisfaction with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Status epilepticus (SE) is a common life-threatening neurological emergency in which prolonged or multiple closely spaced seizures can result in long-term impairments. SE remains associated with considerable mortality and morbidity, with little progress over the last three decades. The proportion of patients who die in the hospital is about 20% overall and 40% in patients with refractory SE. Morbidity is more difficult to evaluate, as adverse effects of SE are often difficult to differentiate from those attributed to the cause of SE. Our experience suggests that nearly 50% of patients may experience long-term functional impairments. The precise description of the consequences of these functional impairments and their impact on quality of life after SE requiring intensive care management has been little studied. Indeed, if cognitive, physical and mental impairments are now identified in the populations of patients who required intensive care under the term postresuscitation syndrome (PICS), neuronal lesions consecutive to the SE itselfor to its cause could be responsible for these different functional alterations.
Thus, the following have been described: (i) cognitive disorders in the areas of attention, executive functions and verbal fluency, visual and working memory disorders, but also spatio-temporal disorders; (ii) physical disorders such as the so-called post-resuscitation polyneuromyopathy; and (iii) mental disorders such as anxiety disorders, depressive states or those related to post-traumatic stress.
Assessment and characterization of patient-reported outcomes is essential to complement the holistic assessment of clinically relevant outcomes from the patient's perspective. The POSEIDON study was a cross-sectional collection of PROs and HR-QOL components, and associated with patient functional outcomes, in those who required ICU management for status epilepticus. We propose here to continue the description of potential alterations after a subsequent ME, namely a longitudinal study (POSEIDON 2) which will also include the evaluation of patient-reported experience (PREMS) and the measurement of family burden.
All patients who meet the eligibility criteria will be offered participation in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
percentage of global impairment of HRQoL
percentage of global impairment of HRQoL defined by one and/or other of the physical and mental impairments (after dichotomization of the SF 36 summary scores compared to the general population) in patients managed in the ICU for or with SE. 36-Item Short Form Survey (SF-36) (HRQoL)-Ranging score\[0-100\], a high score indicate better health status.
Time frame: at 3 month and 12 month
percentage of cognitive impairment in patients managed in the ICU for or with SE
i)The cognitive complaints questionnaire (Questionnaire de Plainte Cognitive (QPC)(Cognition)- a score=3 or more indicate cognitive complaints
Time frame: at 3 month and 12 month
percentage of disability in patients managed in the ICU for or with SE
The Glasgow Outcome Scale extended (Handicap)-Ranging score\[1-8\] a hight score indicate no handicap A score of 5 to 8 on the GOSE indicate a favorable outcome
Time frame: at 3 month and 12 month
percentage of physical dependency in patients managed in the ICU for or with SE
The Lawton IADL (scale contains eight items, with a summary score from 0 (low function) to 8 (high function).and Barthel index (Dependency)-Ranging score\[0-100\], a high score indicate no dependency.
Time frame: at 3 month and 12 month
percentage of anxiety and depression in patients managed in the ICU for or with SE
The Hospital anxiety and depression (Anxiety,Depression)-Ranging score\[0-21\] a score \> 8 indicate in each subscale a depresion or/and anxiety
Time frame: at 3 month and 12 month
percentage of post traumatic syndrome disorder in patients managed in the ICU for or with SE
The Impact of Event Scale -Revised(post traumatic syndrome disorder)-Ranging score\[0-88\],scores higher than 24 are of concern; the higher scores indicate the severity of PTSD
Time frame: at 3 month and 12 month
score of perceived social support by the SSQ6 scale in its 2 dimensions, satisfaction and availability.
The Social Support Questionnaire- Short Form-SSQ6 / 6 item measure of social support, with scores ranging from 0 (no social support) to 6 (very high social) and 1 (very dissatisfied) to 6 (very satisfied) for the area of satisfaction in each item or area. From these scores in the 6 domains, an average score with the support given in each of the areas.
Time frame: at 3 month and 12 month
Presence or absence Post-ICU factors associated of return to work ability in patients managed in the ICU for or with SE.
A return to work will be interpreted by measured by the Work Productivity and Activity Impairment Questionnaire: General Health (WPAI-GH scale) The WPAI-GH consists of six questions: 1 = currently employed; 2 = hours missed due to health problems; 3 = hours missed other reasons; 4 = hours actually worked; 5 = degree health affected productivity while working (using a 0 to 10 Visual Analogue Scale (VAS)); 6 = degree health affected productivity in regular unpaid activities (VAS).. Four main outcomes can be generated from the WPAI-GH and expressed in percentages by multiplying the following scores by 100:
Time frame: at 3 month and 12 month
patient's experience of the care system.
Score measured by the PPE 15 (Picker Patient Experience Questionnaire) of the patient's experience of the healthcare system. It consists of 15 questions distributed to seven dimensions of care: respect, coordination, information/communication/education, physical comfort, emotional support, involvement of relatives, and transitions and continuity The questions have two ("yes" or "no") to four response options ("yes"," no", "I did not need to", or "yes, to some extent"). Neutral answers, such as "I did not need to", and the most positive answer are coded as a "non-problem" (score = 0). The remaining responses are coded as "problems" (score = 1).
Time frame: at 3 month and 12 month
experience of the patient's relative at M3 and M12 of discharge from intensive care following management with or for a patient's ME.
Score measured by ZARIT scale Zarit Burden Interview: Revised (22-items) Total score range: 0 to 88 0-21: no to mild burden 21-40: mild to moderate burden 41-60: moderate to severe burden ≥ 61: severe burden
Time frame: at 3 month and 12 month
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Started May 2024 (actual). Primary completion is estimated for Mar 2027, 34 months after the start.
Of 107 non-industry observational studies under Patient Satisfaction, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 45. This study's planned 34 months is above that.
Counting every sponsor, half of 113 studies reached it within 20 months; a quarter within 7 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Versailles Hospital